Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY)
长效单克隆抗体 Pemivibart 预防 COVID-19 症状的安全性和有效性：3 期随机临床试验 (CANOPY) 的中期结果
期刊:Clinical Infectious Diseases
影响因子:7.3
doi:10.1093/cid/ciaf265
Wolfe, Cameron R; Cohen, Jonathan; Mahoney, Kathryn; Holmes, Anna; Betancourt, Natalia; Gupta, Deepali; Tosh, Kazima; Narayan, Kristin; Campanaro, Ed; Katz, Chloe; Phelan, Anne-Marie; Yalcin, Ilker; Wingertzahn, Mark; Hawn, Pamela; Schmidt, Pete; Li, Yong; Popejoy, Myra
